The study of blood, blood-related organs and tissues (e.g., bone marrow, spleen, and liver), and blood illnesses is known as haematology. Inherited genetic mutations, environmental stressors, and nutritional deficiencies can all cause blood problems. Hemophilia (reduced clotting ability), clotting disorders (predisposition to create blood clots), and blood malignancies (i.e., liquid tumours) such as leukemias, lymphomas, and myelomas are all common haematological illnesses. Because the pharmacological targets of blood disorders are mostly found in the blood, transport and distribution problems are less common than with diseases that affect other parts of the body. Because blood has access to all tissues and organs, this property emphasises the importance of target specificity and constant monitoring of unforeseen consequences. The discovery of novel medications for cancer indications has seen the greatest rapid expansion. The development of tailored medicines for particular patient subgroups characterised by genetic abnormalities is one emphasis in blood drug discovery.
Title : Immuno-Oncology (IO): 2023 and beyond
Stefan Gluck, Global Medical Affairs at Celgene Corporation, United States
Title : Managing bacterial eradication in disease and survival for life support systems on earth and space
A C Matin, Stanford Medical School, United States
Title : Drug discovery for inhibitors of phagocytosis for use in immune cytopenias
Melika Loriamini, University of Toronto, Canada
Title : ABO isoagglutinins inhibit coronavirus infection?
Priyal Shah, University of Toronto, Canada
Title : To assess knowledge on administration of chemotherapy through peripheral and central venous catheter among nurses from tertiary cancer hospital.
Shanti S Nair, Tata Memorial Hospital, India
Title : Impact of cOVID-19 pandemic on transfusion-Dependent thalassemia patients in district battagram
Naveed Akhtar, Hazara University, Pakistan